Alphatec Holdings, Inc. (NASDAQ:ATEC) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine brokerages that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $17.00.

ATEC has been the topic of several research reports. Stifel Nicolaus cut their price target on Alphatec from $19.00 to $16.00 and set a "buy" rating on the stock in a research note on Thursday, August 1st. Needham & Company LLC restated a "buy" rating and issued a $13.00 price target on shares of Alphatec in a report on Thursday, October 31st. Lake Street Capital cut their price objective on shares of Alphatec from $32.00 to $18.00 and set a "buy" rating on the stock in a report on Tuesday, September 3rd. Piper Sandler lowered their target price on Alphatec from $17.00 to $12.00 and set an "overweight" rating for the company in a report on Thursday, August 1st. Finally, Morgan Stanley downgraded Alphatec from an "overweight" rating to an "equal weight" rating in a report on Thursday, August 1st.

Alphatec Trading Down 0.1 %

Shares of NASDAQ:ATEC traded down $0.01 during trading on Friday, reaching $9.40. 2,859,031 shares of the company were exchanged, compared to its average volume of 2,989,489. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. The business's fifty day simple moving average is $6.07 and its 200-day simple moving average is $8.52. Alphatec has a 12-month low of $4.88 and a 12-month high of $17.34.

Insiders Place Their Bets

In other news, Director David M. Demski purchased 50,000 shares of the stock in a transaction on Wednesday, August 21st. The stock was bought at an average price of $5.67 per share, with a total value of $283,500.00. Following the transaction, the director now owns 288,441 shares in the company, valued at $1,635,460.47. The trade was a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 22.80% of the company's stock.

Institutional Trading of Alphatec

Large investors have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. boosted its position in Alphatec by 7.5% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 48,031 shares of the medical technology company's stock worth $662,000 after purchasing an additional 3,363 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in Alphatec by 276.1% in the first quarter. BNP Paribas Financial Markets now owns 99,790 shares of the medical technology company's stock valued at $1,376,000 after purchasing an additional 73,257 shares during the period. Swiss National Bank raised its stake in shares of Alphatec by 1.4% during the 1st quarter. Swiss National Bank now owns 188,300 shares of the medical technology company's stock worth $2,597,000 after buying an additional 2,600 shares during the period. ProShare Advisors LLC lifted its position in shares of Alphatec by 8.5% during the 1st quarter. ProShare Advisors LLC now owns 16,572 shares of the medical technology company's stock valued at $229,000 after buying an additional 1,304 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in Alphatec by 48.1% in the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,125,042 shares of the medical technology company's stock valued at $29,305,000 after acquiring an additional 690,022 shares during the period. 66.35% of the stock is owned by hedge funds and other institutional investors.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.